<SEC-DOCUMENT>0000950170-22-012679.txt : 20220714
<SEC-HEADER>0000950170-22-012679.hdr.sgml : 20220714
<ACCEPTANCE-DATETIME>20220714113152
ACCESSION NUMBER:		0000950170-22-012679
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220711
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220714
DATE AS OF CHANGE:		20220714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EyePoint Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				262774444
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		221082526

	BUSINESS ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-926-5000

	MAIL ADDRESS:	
		STREET 1:		480 PLEASANT STREET
		STREET 2:		SUITE B300
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida Corp.
		DATE OF NAME CHANGE:	20080619

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	pSivida LTD
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eypt-20220711.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-07-14T11:28:08.8298+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:eypt="http://eyepointpharma.com/20220711">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_20e76382-07b9-4cfb-8b25-72d4ec65a4c3" name="dei:AmendmentFlag" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2">false</ix:nonNumeric><ix:nonNumeric id="F_5017d25f-faa3-4237-86b3-e80f5098c991" name="dei:EntityCentralIndexKey" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2">0001314102</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eypt-20220711.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001314102</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14cad8aa-ebcb-4b34-9962-39a3929adaee" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92155d0d-11ef-4493-b76d-5a148ab615e7" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">July 11, 2022</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0398c262-9977-4a68-96fb-6fcf7003627d" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;min-width:fit-content;">EyePoint Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.399%;"></td>
    <td style="width:3.813%;"></td>
    <td style="width:19.399%;"></td>
    <td style="width:17.618%;"></td>
    <td style="width:39.772%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e789559-b9f7-4e17-97bb-f36c15a4adb7" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a69480a-6f48-4ac1-9778-3e01304499e7" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">000-51122</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe648272-8bd1-4af9-b3a2-978eabd30e95" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">26-2774444</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bf7ef91-8ebf-4a13-8980-ea08a65028d1" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">480 Pleasant Street</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5358449-8835-4ae6-9cb0-fe4462a74602" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_390c82f5-848e-49d6-9364-c8a94c557aed" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a333b9c-dfad-4878-979e-f962bff694a3" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68917639-4dab-4d5d-9532-b9cb26439271" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(617)</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da131cd0-5080-4f64-ac87-e0be55bb0a44" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">926-5000</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9722b7e-4d94-49ef-84ed-12686c8c0b6c" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e15e8c9-f4b4-4563-b61c-63d6437c75ce" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d15a59bd-7a4a-42b7-bd83-070fbecacf4c" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.15;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a399c69-8315-463a-ab5d-1f8e9135c136" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e8b24c3-2391-480c-9667-f2444d2b2b00" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Common Stock, par value $0.001</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e99bae58-e2a8-4c14-ba7e-4acc26cc9681" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EYPT</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73919bdc-0d0f-47d7-9944-7f02a39349dd" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The NASDAQ Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_afef2aef-7e7b-4e47-b4d2-218d5ea4e6ea" contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On July 11, 2022, the Board of Directors (the &#x201c;Board&#x201d;) of EyePoint Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;), upon the recommendation of the Governance and Nominating Committee of the Board, increased the size of the Board to eight members and appointed Karen Zaderej to fill the vacancy on the Board, effective immediately. The Board also appointed Ms. Zaderej to the Audit Committee of the Board, effective immediately.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Ms. Zaderej&#x2019;s compensation as a director will be consistent with the compensation provided to all of the Company&#x2019;s non-employee directors.  Under the Company&#x2019;s current non-employee director compensation policy, Ms. Zaderej will receive an annual cash retainer of $45,000 for general availability and participation in meetings and conference calls of the Board.  Ms. Zaderej will receive an additional annual retainer of $10,000 for her service on the Audit Committee. Ms. Zaderej was granted 6,000 restricted stock units and an option to acquire 22,000 shares of common stock of the Company (the &#x201c;Common Stock&#x201d;), with such grants vesting in three equal annual installments commencing on the first anniversary of July 11, 2022, which is the date of the grant.  The option is exercisable for 10 years from the date of grant, with the same per share exercise price as the closing price of the Common Stock on the Nasdaq Global Market on the date of the grant. The restricted stock units and option will also be subject to the terms and conditions of the Company&#x2019;s 2016 Long Term Incentive Plan, as amended, which was filed as Exhibit 10.20 to the Company&#x2019;s Current Report on Form 10-K, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 14, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company also entered into an indemnification agreement with Ms. Zaderej in connection with her appointment to the Board. The indemnification agreement is in substantially the same form as the indemnification agreement for the other directors of the Company filed as Exhibit 10.19 to the Company&#x2019;s Form 10-K filed with the SEC on March 14, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">There is no arrangement or understanding between Ms. Zaderej and any other person pursuant to which Ms. Zaderej was appointed a director of the Company.  There are no relationships or transactions in which Ms. Zaderej has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On July 11, 2022, the Company issued a press release announcing the appointment of Ms. Zaderej to the Board.  A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.943%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:88.053%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.010in;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="eypt-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Press Release by EyePoint Pharmaceuticals, Inc. dated July 11, 2022</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.002%;"></td>
    <td style="width:43.998%;"></td>
    <td style="width:3.998%;"></td>
    <td style="width:46.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">EYEPOINT PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">July 14, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">By:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.250pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">/s/ George O. Elston</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;line-height:1.05;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">George O. Elston<br />Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></span>&#160;</p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eypt-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img96707757_0.jpg" alt="img96707757_0.jpg" style="width:231px;height:45px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">WATERTOWN, Mass., July 11, 2022 (GLOBE NEWSWIRE) &#x2013; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej to its Board of Directors. Ms. Zaderej is currently the President, Chief Executive Officer and Chair of the Board at AxoGen, Inc. and brings more than 35 years of biopharmaceutical and medical device experience to the role.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;We are thrilled to welcome Ms. Zaderej to our Board of Directors,&#x201d; said Nancy Lurker, Chief Executive Officer at EyePoint Pharmaceuticals. &#x201c;Karen&#x2019;s passion for discovering innovative solutions in medicine, coupled with her track record of successful drug and medical device development and commercial leadership make her a compelling addition to the Board. We look forward to her valuable insight as we continue to advance the clinical development of our lead pipeline asset, EYP-1901, for multiple ophthalmic indications and our commercial products, based on our proprietary and proven Durasert</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#174;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> technology for sustained intraocular drug delivery.&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;We are excited to welcome Ms. Zaderej to our Board of Directors and leverage her strategic life science and commercial experience to deliver new treatment options for people living with serious eye disorders,&#x201d; said Dr. G&ouml;ran Ando, M.D., Chair of the Board of EyePoint Pharmaceuticals. &#x201c;Karen brings a deep level of industry knowledge to this role informed by her tremendous leadership experience in biotech, and we are confident that her appointment will help drive EyePoint&#x2019;s goal of becoming the leader in innovative ocular drug delivery technology.&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Ms. Zaderej currently serves as President, Chief Executive Officer, and Chair of the Board at AxoGen. Earlier in her career, she held positions of increasing responsibility at AxoGen, including Chief Operating Officer and Vice President of Marketing and Sales. Prior to joining AxoGen in 2006, Ms. Zaderej worked for Zaderej Medical Consulting, a consulting firm she founded to assist medical device companies to build and execute successful commercialization plans. Previously, she worked at Ethicon, Inc., a Johnson &amp; Johnson company, where she held senior positions in marketing, business development, research &amp; development, and manufacturing. Ms. Zaderej is a member of the University of Tampa Board of Trustees and the MedExec Women Board of Advisors. She holds an M.B.A. from the Kellogg Graduate School of Business and a B.S. in Chemical Engineering from Purdue University.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;It is a privilege to join EyePoint&#x2019;s Board of Directors at such an exciting time for the Company, as EYP-1901 is well positioned as a potentially paradigm-shifting product for the treatment of wet AMD,&#x201d; said Karen Zaderej. &#x201c;I look forward to working closely with my fellow Board members to support the Company&#x2019;s strategic objectives as it continues to advance its innovative ophthalmic pipeline.&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">About EYP-1901</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">EYP-1901 is being developed as an investigational sustained delivery treatment, initially in wet age-related macular degeneration combining a bioerodible formulation of EyePoint's proprietary Durasert</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#174;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> delivery technology with vorolanib, a tyrosine kinase inhibitor. Positive interim eight-month safety and efficacy data from the ongoing DAVIO Phase 1 clinical trial of EYP-1901 showed no reports of ocular or drug-related systemic SAEs and no dose limiting toxicities with stable visual acuity and OCT. Further, 53% and 41% of eyes did not require any supplemental anti-VEGF injections up to six and nine months, respectively, following a single dose of EYP-1901. Phase 2 studies are planned for wet AMD and non-proliferative diabetic retinopathy in 2022 and diabetic macular edema in 2023. Vorolanib is licensed to EyePoint exclusively by Equinox Sciences for the localized treatment of all ophthalmic diseases.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.5pt;font-family:Arial;min-width:fit-content;">  </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.5pt;font-family:Arial;min-width:fit-content;">     </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.5pt;font-family:Arial;min-width:fit-content;">  </font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">About EyePoint Pharmaceuticals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert&#174; technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">&#174;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">EYEPOINT PHARMACEUTICALS SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the use of proceeds for the offering and other statements identified by words such as &#x201c;will,&#x201d; &#x201c;potential,&#x201d; &#x201c;could,&#x201d; &#x201c;can,&#x201d; &#x201c;believe,&#x201d; &#x201c;intends,&#x201d; &#x201c;continue,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;estimates,&#x201d; &#x201c;may,&#x201d; other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint&#x2019;s actual results to be materially different than those expressed in or implied by EyePoint&#x2019;s forward-looking statements. For EyePoint, this includes stock price volatility and uncertainties relating to the financial markets, the continued impact of the COVID-19 pandemic on EyePoint&#x2019;s business, the medical community and the global economy, and the impact of general business and economic conditions. More detailed information on these and additional factors that could affect EyePoint&#x2019;s actual results are described in EyePoint&#x2019;s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. All forward-looking statements in this news release speak only as of the date of this news release. EyePoint undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Investors:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Christina Tartaglia<br>Stern IR<br>Direct: 212-698-8700<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">christina.tartaglia@sternir.com</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Media Contact:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"></font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Amy Phillips</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Green Room Communications</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">Direct: 412-327-9499</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;">aphillips@greenroompr.com</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.5pt;font-family:Arial;min-width:fit-content;">  </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.5pt;font-family:Arial;min-width:fit-content;">     </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2649999999999997;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.5pt;font-family:Arial;min-width:fit-content;">  </font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img96707757_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img96707757_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ 3$# 2(  A$! Q$!_\0
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MYT,SN.7!V;2?]H;2#^=?4,/^HC_W1_*IJQ<813\Q25DC&\9_\B/KO_7A/_Z
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>eypt-20220711_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-07-14T11:28:08.7548+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>eypt-20220711_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-07-14T11:28:08.7580+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eypt-20220711.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>eypt-20220711.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-07-14T11:28:08.7104+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://eyepointpharma.com/20220711" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:eypt="http://eyepointpharma.com/20220711" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20220711_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eypt-20220711_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139835412177552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 11,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EyePoint Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2774444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">480 Pleasant Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">926-5000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYPT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>eypt-20220711_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eypt-20220711.xsd" xlink:type="simple"/>
    <context id="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314102</identifier>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_20e76382-07b9-4cfb-8b25-72d4ec65a4c3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_5017d25f-faa3-4237-86b3-e80f5098c991">0001314102</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_14cad8aa-ebcb-4b34-9962-39a3929adaee">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_92155d0d-11ef-4493-b76d-5a148ab615e7">2022-07-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_0398c262-9977-4a68-96fb-6fcf7003627d">EyePoint Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_5e789559-b9f7-4e17-97bb-f36c15a4adb7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_7a69480a-6f48-4ac1-9778-3e01304499e7">000-51122</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_fe648272-8bd1-4af9-b3a2-978eabd30e95">26-2774444</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_3bf7ef91-8ebf-4a13-8980-ea08a65028d1">480 Pleasant Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_e5358449-8835-4ae6-9cb0-fe4462a74602">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_390c82f5-848e-49d6-9364-c8a94c557aed">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_6a333b9c-dfad-4878-979e-f962bff694a3">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_68917639-4dab-4d5d-9532-b9cb26439271">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_da131cd0-5080-4f64-ac87-e0be55bb0a44">926-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_b9722b7e-4d94-49ef-84ed-12686c8c0b6c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_1e15e8c9-f4b4-4563-b61c-63d6437c75ce">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_d15a59bd-7a4a-42b7-bd83-070fbecacf4c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_5a399c69-8315-463a-ab5d-1f8e9135c136">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_5e8b24c3-2391-480c-9667-f2444d2b2b00">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_e99bae58-e2a8-4c14-ba7e-4acc26cc9681">EYPT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_73919bdc-0d0f-47d7-9944-7f02a39349dd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2"
      id="F_afef2aef-7e7b-4e47-b4d2-218d5ea4e6ea">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MMB\\-HY 9';YXP5LFA1JU0(X;>+O44?V#*=ZJE;U'926>\9*T>:[V&_AJM;
M:6]_#U<6XEBK5YD$]8FD-1^&%%K5+3AM\N_1QBHS:'E_R?3PZJ 5/;_=)5=Q
MU2XX[?/%' YQHWL8A1;XT.'=CQ1*U1 X[>-?%#88[#<JH2RN0>02E^<Y&AU%
M5/4"3IOWLY;&0&+=/\Z3K7-DM53_KPOPJ@UPVL,G*I*!-+8U/=CU(T54RT.K
M-/'X51?P:9\>:S@-,#V *VRS/\0M&NYDO\[G]?/7H-=(5EF_3_OT=V3W698C
M62,@+=L(N+?CIVUZ*@TV<S5GW/\P^\@F$.18;[5[C 8E6Y_8TB9&!2\G+!6:
MO8HH!_:CU\*]$05;>;]/F_54B] 6W60=SU1MR34(W/XYGE(DE='[M"GO\L1N
MWX*E2!9P<(?;(/0XG-P,?ZMC<O=>-.U+^X.PF\&,13!'):_517?6F_?@S8E1
M:?'N.5,&WV2+PR4(+#,[ *_/E3*[$_LZ6_X:,?@/4$L#!!0    ( /A;[E2?
MH!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1
M&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMW
MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<
M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20
MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!
M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B
M+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM
M(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS
M8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS
MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5
M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S
MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41
MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS
M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U
M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,
M/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#
M!!0    ( /A;[E27BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,
M0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BD
MMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G
M<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^
M=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"
MR0_L?@!02P,$%     @ ^%ON5#JJHN=  0  / (   \   !X;"]W;W)K8F]O
M:RYX;6R-45UKPS ,_"O&/V!)RU98:09CW4=A;&4=?7=BI1&UK6"K[=9?/R4A
MK+"7/<DZB=/=>7&BN"^)]NK+NY *W3"W\RQ+50/>I"MJ(<BDIN@-2QMW66HC
M&)L: /8NF^;Y+/,&@[Y;C%SKF%TVQ% Q4A"P [8(I_0[[UIUQ(0E.N3O0O=O
M!UIY#.CQ#+;0N5:IH=,+13Q38.,V523G"CT9!EN(C-4?>-.)_#1EZA$VY8<1
M(86>Y4)88TS<;_3\1C0>09:'[L#TA(XA+@W#<Z1#BV'7T8B+[,)&G\-8AQ#G
M\3\Q4EUC!4NJ#AX"#SE&<)W D!ILDU;!>"CTN*+N@U6/@24DM0H#E>QV3N7T
MR@ZN6>1>9!CG*(.XLH/P4:V%&@/8-SF0!)?DJG547>EYIM<WDUM)Z.#<@V#O
MX96,'<V/'W?W U!+ P04    " #X6^Y4)!Z;HJT   #X 0  &@   'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %
M\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HN
MSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=
MZ*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W
M]T6NS>,)KM\,<'AT_@%02P,$%     @ ^%ON5&60>9(9 0  SP,  !,   !;
M0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:
MJ_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)X
MKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\
MC<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)
M7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\
MP68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B
M6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #X6^Y4
M!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    ( /A;[E14*!^&[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( /A;[E297)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ ^%ON5)8H'.A5!   F1   !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /A;[E2?H!OPL0(  .(,
M   -              "  9D,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M^%ON5)>*NQS     $P(   L              ( !=0\  %]R96QS+RYR96QS
M4$L! A0#%     @ ^%ON5#JJHN=  0  / (   \              ( !7A
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /A;[E0D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( /A;[E1ED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eypt-20220711.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="eypt-20220711.htm">eypt-20220711.htm</File>
    <File>eypt-20220711.xsd</File>
    <File>eypt-20220711_lab.xml</File>
    <File>eypt-20220711_pre.xml</File>
    <File>eypt-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "eypt-20220711.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "eypt-20220711.htm"
     ]
    },
    "labelLink": {
     "local": [
      "eypt-20220711_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eypt-20220711_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "eypt-20220711.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "eypt",
   "nsuri": "http://eyepointpharma.com/20220711",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-20220711.htm",
      "contextRef": "C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "eypt-20220711.htm",
      "contextRef": "C_e5bbfd52-19f0-4e3f-9308-d0f552d2d2a2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eyepointpharma.com/20220711/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-22-012679-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-012679-xbrl.zip
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MH.<X%E$T(A_"F,5^R"+2K;K<AS'Z#7(41>0":V7D0F0BO1:\@4W^=-C+ 18
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M9CN">5Q7A&NNAV0OV>U)F;WA2^&\V?2K652S;0/^/"'TL\0:L=^2,5)X6Z]
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MIXFQT(ZC$O4@X3,T.*9B086(F]>\$^-WRJZ:)9="^\#(4&' T%(1%3LY>N%
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MF=:\L>KSLF4_YKDDUEIG_',6.\^A(>LH'(!]3BH=['"E_^J*V*#ZCC)KAC0
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M3X/^#U!+ 0(4 Q0    ( /A;[E04$-#2DQ8  *;7   1              "
M 0    !E>7!T+3(P,C(P-S$Q+FAT;5!+ 0(4 Q0    ( /A;[E321";L$P,
M *H)   1              "  <(6  !E>7!T+3(P,C(P-S$Q+GAS9%!+ 0(4
M Q0    ( /A;[E2C+./ F04  /TQ   5              "  00:  !E>7!T
M+3(P,C(P-S$Q7VQA8BYX;6Q02P$"% ,4    " #X6^Y4-XB]4XH$  #P)
M%0              @ '0'P  97EP="TR,#(R,#<Q,5]P<F4N>&UL4$L! A0#
M%     @ ^%ON5'=H)-">#@  (50   \              ( !C20  &5Y<'0M
@97@Y.5\Q+FAT;5!+!08     !0 % $$!  !8,P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
